Hyperglycemia with acarbose was associated with a 49% relative risk reduction These patients were also followed up for outcome parameters. Prematurely, 211 in the acarbose-treated group and 130 in the placebo group
Results Three hundred forty-one patients (24%) discontinued their participation Peripheral vascular disease) and hypertension (≥140/90 mm Hg). Main Outcome Measures The development of major cardiovascular events (coronary heart disease,Ĭardiovascular death, congestive heart failure, cerebrovascular event, and
Or 100 mg of acarbose 3 times a day (n = 714). Intervention Patients with IGT were randomized to receive either placebo (n = 715) These patients were followed up for a mean (SD) of 3.3 (1.2) years. With a mean (SD) age of 54.5 (7.9) years and body mass index of 30.9 (4.2). Both men (49%) and women (51%) participated They did not have IGT or had no postrandomization data, leaving 1368 patientsįor a modified intent-to-treat analysis. Of 1429 patients with IGT were randomized with 61 patients (4%) excluded because Sweden, Finland, Israel, and Spain from July 1998 through August 2001. Trial, undertaken in hospitals in Canada, Germany, Austria, Norway, Denmark, Objective To evaluate the effect of decreasing postprandial hyperglycemia withĪcarbose, an α-glucosidase inhibitor, on the risk of cardiovascularĭisease and hypertension in patients with impaired glucose tolerance (IGT).ĭesign, Setting, and Participants International, multicenter double-blind, placebo-controlled, randomized
0 kommentar(er)
